Efavaleukin alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Efavaleukin alfa Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Discontinued
Highest phase
9
Registered trials
10
Result records
67
Matched deals
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether Efavaleukin alfa can convert its Interleukins profile and IL-2R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Efavaleukin alfa (query alias: efavaleukin alfa) |
|---|---|
| Modality / target | Interleukins; IL-2R; IL-2R agonists |
| Highest global status | Discontinued |
| Originator | Amgen, Inc. |
| Active developers | Not disclosed |
The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04987307 | Phase 2 | Terminated | 221 | Percentage of Participants With Clinical Remission at Week 12 |
| NCT05672199 | Phase 2 | Terminated | 25 | Number of Participants with Treatment-emergent Adverse Events (TEAEs) |
| NCT05873907 | Phase 1 | Completed | 64 | Number of Participants with Treatment-emergent Adverse Events (TEAEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Phase 2; n=221; evaluation: not stated. Reported fields: Percentage of Participants With Clinical Remission at Week 12: Difference percentage (%) = 2.1(95% CI, -8.6 to 12.8), P-Value = 0.70; Difference % = 2.0(95% CI, -8.6 to 12.6), P-Value = 0.72; Difference % = 3.1(95% CI, -8.0 to 14.2), P-Value = 0.58; Percentage of Participants With Clinical Remission at Week 12: Difference percentage (%) = 2.1(95% CI, -8.6 to 12.8), P-Value = 0.70; Difference % = 2.0(95% CI, -8.6 to 12.6), P-Value = 0.72; Difference % = 3.1(95% CI, -8.0 to 14.2), P-Value = 0.58; Percentage of Participants With Clinical Remission at Week 12 = 9.8 percentage of participants
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
Phase 2; n=168; evaluation: not stated. Reported fields: Number of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response at Week 52 = 8 Participants ; -; -
TARGETING IMPROVED TREG SELECTIVITY WITH THE IL-2 MUTEIN EFAVALEUKIN ALFA: RATIONALE FOR IL-2 THERAPY IN ULCERATIVE COLITIS
Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Adverse Event: injection site reactions = The most common AEs were mild-moderate (grade 1-2) injection site reactions. No dose-limiting toxicities, treatment-related serious AEs, or deaths were reported
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Efavaleukin alfa addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Interleukins—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 67 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IL-2R records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-02-19 | ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch | Approved | Financial terms not disclosed |
| 2026-02-11 | Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar | Approved | Financial terms not disclosed |
| 2026-01-14 | Biopharma Cigalah to distribute ImmunityBio' ANKTIVA plus Bacillus Calmette-Guerin for BCG-unresponsive NMIBC in Saudi Arabia | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
